Myriad Genetics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Myriad Genetics, Inc. (MYGN)

NEW YORK CITY, NY / ACCESS Newswire / August 5, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning potential violations of the federal securities laws.

Myriad Genetics shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million -- down roughly 11% year over year and 7% to 8% below Wall Street consensus of about $206-208 million -- and simultaneously cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million.

Alongside the revenue cut, the Company lowered gross margin expectations and suspended its adjusted EBITDA guidance entirely. The previously issued adjusted EBITDA range was $37 million to $49 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance.

The timing is central to the investigation. On May 5, 2026, Myriad Genetics reiterated its full-year 2026 revenue guidance range of $860 million to $880 million. That range was reduced by approximately $90 million at the midpoint roughly three months later. The Company's Q1 2026 Form 10-Q, filed May 6, 2026, reported trade accounts receivable of $123.8 million as of March 31, 2026, compared with $115.3 million as of December 31, 2025, and net cash used in operating activities of $15.7 million.

If you suffered a loss on your Myriad Genetics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP